209 related articles for article (PubMed ID: 26273714)
1. Biomedical research: Drug hunters wanted.
Perkel JM
Nature; 2015 Aug; 524(7564):257-8. PubMed ID: 26273714
[No Abstract] [Full Text] [Related]
2. From the Editor: New drugs, old lessons.
Brown WV
J Clin Lipidol; 2016; 10(1):1-2. PubMed ID: 26892117
[No Abstract] [Full Text] [Related]
3. Heart drug pushes outcome-based pricing plans.
Senior M
Nat Rev Drug Discov; 2015 Oct; 14(10):665-7. PubMed ID: 26424350
[No Abstract] [Full Text] [Related]
4. PCSK9 inhibitors are go.
Mullard A
Nat Rev Drug Discov; 2015 Sep; 14(9):593. PubMed ID: 26323538
[No Abstract] [Full Text] [Related]
5. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
Schulman KA; Balu S; Reed SD
N Engl J Med; 2015 Oct; 373(17):1591-3. PubMed ID: 26444460
[No Abstract] [Full Text] [Related]
6. PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
EBioMedicine
EBioMedicine; 2015 Dec; 2(12):1835. PubMed ID: 26844247
[No Abstract] [Full Text] [Related]
7. Alirocumab (Praluent) to lower LDL-Cholesterol.
Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
[No Abstract] [Full Text] [Related]
8. Turning the Titanic.
Zerhouni EA
Sci Transl Med; 2014 Jan; 6(221):221ed2. PubMed ID: 24476998
[No Abstract] [Full Text] [Related]
9. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].
Lettino M
G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756
[No Abstract] [Full Text] [Related]
10. New class PCSK9 blockers stride into cholesterol market.
Sheridan C
Nat Biotechnol; 2015 Aug; 33(8):785-6. PubMed ID: 26252118
[No Abstract] [Full Text] [Related]
11. [First PCSK9 inhibitor].
Westphal K
MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27462666
[No Abstract] [Full Text] [Related]
12. [First PCSK9 inhibitor].
Westphal K
MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324017
[No Abstract] [Full Text] [Related]
13. [2nd PCSK9 inhibitor for effective LDL decrease].
Einecke D
MMW Fortschr Med; 2016 Feb; 158(2):65. PubMed ID: 26961048
[No Abstract] [Full Text] [Related]
14. Inhibition of PCSK9: is this the way forward for managing residual risk?
Chowdhury SR; Rees A
Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
[No Abstract] [Full Text] [Related]
15. Cholesterol-lowering blockbuster candidates speed into Phase III trials.
Mullard A
Nat Rev Drug Discov; 2012 Nov; 11(11):817-9. PubMed ID: 23123928
[No Abstract] [Full Text] [Related]
16. Finding the Right Price for Improving Care.
Charlton B
JAMA Intern Med; 2016 Jan; 176(1):109. PubMed ID: 26662340
[No Abstract] [Full Text] [Related]
17. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
Tice JA; Kazi DS; Pearson SD
JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
[No Abstract] [Full Text] [Related]
18. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
[No Abstract] [Full Text] [Related]
19. [PCSK9 inhibitor is convincing a large analysis].
Schlimpert V
MMW Fortschr Med; 2015 Dec; 157(21-22):90. PubMed ID: 26960892
[No Abstract] [Full Text] [Related]
20. Familial hypercholesterolaemia: PCSK9 inhibitors are coming.
Santos RD; Watts GF
Lancet; 2015 Jan; 385(9965):307-10. PubMed ID: 25282517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
